Mifamurtide

• CAT Number: I005009
• CAS Number: 83461-56-7
• Molecular Formula: C59H109N6O19P
• Molecular Weight: 1237.5
• Purity: ≥95%
• Target: Others
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C

Mifamurtide(CGP19835; MTP-PE) is a drug against osteosarcoma.Target: OthersMifamurtide is an immunomodulator with antitumor effects that appear to be mediated via activation of monocytes and macrophages. Mifamurtide is generally well tolerated; adverse events attributed to administration of the drug include chills, fever, headache, nausea, and myalgias. Based on the available data, mifamurtide can be considered for inclusion in treatment protocols for localized osteosarcoma [1]. Mifamurtide has orphan drug status for the treatment of osteosarcoma in the US and EU [2].

Reference

1:The role of mifamurtide in chemotherapy-induced osteoporosis of children with osteosarcoma. Giulia B, Daniela DP, Chiara T, Iolanda M, Francesca P, Fiorina C, Francesca R.Curr Cancer Drug Targets. 2016 Dec 15. [Epub ahead of print] PMID: 27993113 2:Lifetime effectiveness of mifamurtide addition to chemotherapy in nonmetastatic and metastatic osteosarcoma: a Markov process model analysis. Song HJ, Lee JA, Han E, Lee EK.Tumour Biol. 2015 Sep;36(9):6773-9. doi: 10.1007/s13277-015-3405-3. Epub 2015 Apr 3. PMID: 25835978 3:Economic Considerations On the Use of Mifamurtide In the Treatment of Osteosarcoma In Spain. Brosa M, García del MX, Mora J, Villacampa A, Pozo T, Adán C, Grande M, García E, Cubells L.Value Health. 2014 Nov;17(7):A526-7. doi: 10.1016/j.jval.2014.08.1662. Epub 2014 Oct 26. No abstract available. PMID: 27201662 Free Article4:Orphan drugs revisited: cost-effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcoma. Brosa M, García del Muro X, Mora J, Villacampa A, Pozo-Rubio T, Cubells L, Montoto C.Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):331-40. doi: 10.1586/14737167.2015.972378. Epub 2014 Oct 29. PMID: 25354299 5:The addition of mifamurtide to chemotherapy improves lifetime effectiveness in children with osteosarcoma: a Markov model analysis. Song HJ, Lee EK, Lee JA, Kim HL, Jang KW.Tumour Biol. 2014 Sep;35(9):8771-9. doi: 10.1007/s13277-014-2139-y. Epub 2014 May 30. PMID: 24874050 6:Mifamurtide for high-grade, resectable, nonmetastatic osteosarcoma following surgical resection: a cost-effectiveness analysis. Johal S, Ralston S, Knight C.Value Health. 2013 Dec;16(8):1123-32. doi: 10.1016/j.jval.2013.08.2294. Epub 2013 Oct 3. PMID: 24326165 Free Article7:Synthesis of isotopically labeled versions of L-MTP-PE (mifamurtide) and MDP. Li Y, Plesescu M, Prakash SR.J Labelled Comp Radiopharm. 2013 Jul-Aug;56(9-10):475-9. doi: 10.1002/jlcr.3078. Epub 2013 Jul 9. PMID: 24285524 8:Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment. Venkatakrishnan K, Liu Y, Noe D, Mertz J, Bargfrede M, Marbury T, Farbakhsh K, Oliva C, Milton A.Br J Clin Pharmacol. 2014 Jun;77(6):998-1010. doi: 10.1111/bcp.12261. PMID: 24134216 Free PMC Article9:Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment. Venkatakrishnan K, Liu Y, Noe D, Mertz J, Bargfrede M, Marbury T, Farbakhsh K, Oliva C, Milton A.Br J Clin Pharmacol. 2014 Jun;77(6):986-97. doi: 10.1111/bcp.12260. PMID: 24134181 Free PMC Article10:Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments. Anderson PM, Meyers P, Kleinerman E, Venkatakrishnan K, Hughes DP, Herzog C, Huh W, Sutphin R, Vyas YM, Shen V, Warwick A, Yeager N, Oliva C, Wang B, Liu Y, Chou A.Pediatr Blood Cancer. 2014 Feb;61(2):238-44. doi: 10.1002/pbc.24686. Epub 2013 Aug 31. PMID: 23997016 Free PMC Article